173 related articles for article (PubMed ID: 18190632)
1. Use of androgen deprivation therapy for metastatic prostate cancer in older men.
Keating NL; O'Malley AJ; McNaughton-Collins M; Oh WK; Smith MR
BJU Int; 2008 May; 101(9):1077-83. PubMed ID: 18190632
[TBL] [Abstract][Full Text] [Related]
2. Trends and racial differences in the use of androgen deprivation therapy for metastatic prostate cancer.
Carson AP; Howard DL; Carpenter WR; Taylor YJ; Peacock S; Schenck AP; Godley PA
J Pain Symptom Manage; 2010 May; 39(5):872-81. PubMed ID: 20471547
[TBL] [Abstract][Full Text] [Related]
3. Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies.
Gravis G; Boher JM; Chen YH; Liu G; Fizazi K; Carducci MA; Oudard S; Joly F; Jarrard DM; Soulie M; Eisenberger MJ; Habibian M; Dreicer R; Garcia JA; Hussain MHM; Kohli M; Vogelzang NJ; Picus J; DiPaola R; Sweeney C
Eur Urol; 2018 Jun; 73(6):847-855. PubMed ID: 29475737
[TBL] [Abstract][Full Text] [Related]
4. Racial, Socioeconomic, and Geographic Disparities in the Receipt, Timing to Initiation, and Duration of Adjuvant Androgen Deprivation Therapy in Men with Prostate Cancer.
Nguyen C; Lairson DR; Swartz MD; Du XL
J Racial Ethn Health Disparities; 2019 Feb; 6(1):133-142. PubMed ID: 29959759
[TBL] [Abstract][Full Text] [Related]
5. Race and Time to Receipt of Androgen Deprivation Therapy Among Men With Metastatic Prostate Cancer.
Cobran EK; Young HN; Chen RC; Chen X; Reeves J; Godley PA; Shah S
J Natl Med Assoc; 2019 Jun; 111(3):246-255. PubMed ID: 30389146
[TBL] [Abstract][Full Text] [Related]
6. Androgen deprivation therapy and the risk of parkinsonism in men with prostate cancer.
Young JWS; Sutradhar R; Rangrej J; Marras C; Fleshner N; Alibhai SMH
World J Urol; 2017 Sep; 35(9):1417-1423. PubMed ID: 28204918
[TBL] [Abstract][Full Text] [Related]
7. Differential use of medical versus surgical androgen deprivation therapy for patients with metastatic prostate cancer.
Borno HT; Lichtensztajn DY; Gomez SL; Palmer NR; Ryan CJ
Cancer; 2019 Feb; 125(3):453-462. PubMed ID: 30444526
[TBL] [Abstract][Full Text] [Related]
8. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Impact of Serum Testosterone and Body Mass Index Before Androgen-deprivation Therapy in Metastatic Prostate Cancer.
Shiota M; Takeuchi A; Sugimoto M; Kashiwagi E; Dejima T; Kiyoshima K; Inokuchi J; Tatsugami K; Yokomizo A
Anticancer Res; 2015 Dec; 35(12):6925-32. PubMed ID: 26637918
[TBL] [Abstract][Full Text] [Related]
10. [Androgen deprivation for advanced prostate cancer].
Heidenreich A; Pfister D; Ohlmann CH; Engelmann UH
Urologe A; 2008 Mar; 47(3):270-83. PubMed ID: 18273599
[TBL] [Abstract][Full Text] [Related]
11. Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone-sensitive prostate cancer.
Sathianathen NJ; Oestreich MC; Brown SJ; Gupta S; Konety BR; Dahm P; Kunath F
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013245. PubMed ID: 33314020
[TBL] [Abstract][Full Text] [Related]
12. Serum testosterone level predicts the effective time of androgen deprivation therapy in metastatic prostate cancer patients.
Wang Y; Dai B; Ye DW
Asian J Androl; 2017; 19(2):178-183. PubMed ID: 26975487
[TBL] [Abstract][Full Text] [Related]
13. Detectable prostate-specific antigen Nadir during androgen-deprivation therapy predicts adverse prostate cancer-specific outcomes: results from the SEARCH database.
Keto CJ; Aronson WJ; Terris MK; Presti JC; Kane CJ; Amling CL; Freedland SJ
Eur Urol; 2014 Mar; 65(3):620-7. PubMed ID: 23245686
[TBL] [Abstract][Full Text] [Related]
14. Androgen Deprivation Therapy and Outcomes After Radiation Therapy in Black Patients With Prostate Cancer.
Morgan KM; Riviere P; Nelson TJ; Guram K; Deshler LN; Sabater Minarim D; Duran EA; Banegas MP; Rose BS
JAMA Netw Open; 2024 Jun; 7(6):e2415911. PubMed ID: 38857047
[TBL] [Abstract][Full Text] [Related]
15. Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial.
Warde P; Mason M; Ding K; Kirkbride P; Brundage M; Cowan R; Gospodarowicz M; Sanders K; Kostashuk E; Swanson G; Barber J; Hiltz A; Parmar MK; Sathya J; Anderson J; Hayter C; Hetherington J; Sydes MR; Parulekar W;
Lancet; 2011 Dec; 378(9809):2104-11. PubMed ID: 22056152
[TBL] [Abstract][Full Text] [Related]
16. Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer.
Greenspan SL; Coates P; Sereika SM; Nelson JB; Trump DL; Resnick NM
J Clin Endocrinol Metab; 2005 Dec; 90(12):6410-7. PubMed ID: 16189261
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of androgen deprivation therapy in prolonging survival of older men treated for locoregional prostate cancer.
Holmes L; Chan W; Jiang Z; Du XL
Prostate Cancer Prostatic Dis; 2007; 10(4):388-95. PubMed ID: 17486111
[TBL] [Abstract][Full Text] [Related]
18. Androgen deprivation increases the risk of fracture in prostate cancer patients: a population-based study in Chinese patients.
Wu CT; Yang YH; Chen PC; Chen MF; Chen WC
Osteoporos Int; 2015 Sep; 26(9):2281-90. PubMed ID: 25990353
[TBL] [Abstract][Full Text] [Related]
19. Androgen Deprivation Therapy for Prostate Cancer and the Risk of Venous Thromboembolism.
Klil-Drori AJ; Yin H; Tagalakis V; Aprikian A; Azoulay L
Eur Urol; 2016 Jul; 70(1):56-61. PubMed ID: 26138040
[TBL] [Abstract][Full Text] [Related]
20. Impact of ethnicity on the outcome of men with metastatic, hormone-sensitive prostate cancer.
Bernard B; Muralidhar V; Chen YH; Sridhar SS; Mitchell EP; Pettaway CA; Carducci MA; Nguyen PL; Sweeney CJ
Cancer; 2017 May; 123(9):1536-1544. PubMed ID: 28055108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]